Explore /
Poster
/ Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma.

Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma.

Authors

Bennett Adam Caughey

Division of Medical Oncology, Duke University School of Medicine, Durham, NC

Bennett Adam Caughey , Kumiko Umemoto , Michelle Green , Masafumi Ikeda , Rachel D'Anna , Makoto Ueno , Donna Niedzwiecki , Hiroya Taniguchi , Daniel Walden , Yoshito Komatsu , Katherine I. Zhou , Taito Esaki , Ryne Ramaker , Tadamichi Denda , Michael Datto , Hideaki Bando , Tanios S. Bekaii-Saab , Takayuki Yoshino , John H Strickler , Yoshiaki Nakamura

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3571)

DOI

10.1200/JCO.2022.40.16_suppl.3571

Abstract #

3571

Poster Bd #

365

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Gastrointestinal Cancers Symposium

<span>Association of candidate alterations with primary resistance to </span><em>KRAS G12D </em><span>targeting in colorectal cancer.</span>

Association of candidate alterations with primary resistance to KRAS G12D targeting in colorectal cancer.

First Author: Khalid Jazieh

Poster

2024 ASCO Gastrointestinal Cancers Symposium

<span fontscheme="2">Association of class II and III </span><em fontscheme="2">BRAF</em><span fontscheme="2"> mutations with EGFR blockade therapy response and representation of molecularly distinct subgroups of </span><em fontscheme="2">BRAF </em><span fontscheme="2">mutations in MMR proficient CRC.</span>

Association of class II and III BRAF mutations with EGFR blockade therapy response and representation of molecularly distinct subgroups of BRAF mutations in MMR proficient CRC.

First Author: Ibrahim Halil Sahin

Poster

2023 ASCO Gastrointestinal Cancers Symposium

Mutation status of full <em>RAS</em> and <em>BRAF</em> in 169 Moroccan patients with colorectal cancer.

Mutation status of full RAS and BRAF in 169 Moroccan patients with colorectal cancer.

First Author: Sara El Zaitouni

Poster

2023 ASCO Gastrointestinal Cancers Symposium

A plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC).

First Author: Anwaar Saeed

FEATURED

Identification of an optimal circulating tumor DNA (ctDNA) shedding threshold to detect actionable driver mutations in colorectal and pancreatic adenocarcinoma.

Authors

Bennett Adam Caughey

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Association of candidate alterations with primary resistance to KRAS G12D targeting in colorectal cancer.

Poster

Association of class II and III BRAF mutations with EGFR blockade therapy response and representation of molecularly distinct subgroups of BRAF mutations in MMR proficient CRC.

Poster

Mutation status of full RAS and BRAF in 169 Moroccan patients with colorectal cancer.

Poster

A plasma-based analysis and genomic landscape of patients with high tumor mutational burden (TMB-H), microsatellite stable (MSS) colorectal cancer (CRC).